期刊文献+

雷贝拉唑钠对幽门螺杆菌的体外抑菌效果观察 被引量:7

In- Vitro Activity of Rabeprazole (Bolite) against Helicobacter pylori
下载PDF
导出
摘要 目的观察质子泵抑制剂雷贝拉唑钠对幽门螺杆菌的抑制作用。方法应用平板掺入法研究雷贝拉唑钠(波利特)对幽门螺杆菌的体外抑菌作用。结果 发现雷贝拉唑钠在体外对幽门螺杆菌具有明显的抑菌作用(MIC99为2.25μg/ml),其体外抑菌作用强于奥美拉唑(洛赛克)。结论本研究结果提示雷贝拉唑钠对幽门螺杆菌的直接抑菌作用可能在幽门螺杆菌感染的治疗中有重要作用。 Objective Rabeprazole is a gastric parietal. cell proton pump inhibitor, the aim of this study was to investigate its activity against Helicobacter pylori in vitro. Method We investigated its and imicrobial effect by deter- mining the MICs for 3H. pylori strains isolated from different ountries. Results The MIC99 was 2.25μg/ml for all the 3 strains, exhibiting a stronger inhibitory activity in vitro than Omeprazole. Conclusion It suggested that Rebaprazole contributed in the treatment of H. pylori infection not only for its anti - secretion of acid but also for its anti H. plori activity.
出处 《疾病监测》 CAS 2002年第12期452-454,共3页 Disease Surveillance
关键词 体外抑菌效果 质子泵抑制剂 幽门螺杆菌 雷贝拉唑 消化道溃疡 PPI Helicobacter pylori Rabeprazole
  • 相关文献

参考文献4

  • 1Miwa H, Yamada T, Sato K, et al. Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection: comparison of 20 and 40 mg rabeprazole with 60 mg lansoprazole. Dig Dis Sci, 2000,45(1) :77 - 82
  • 2Tsuchiya M, Imamura L, Park JB, et al. Helicobacter pylori urease inhibition by rabeprazole, a proton pump inhibitor. Biol Pharm Bull,1995,18(8): 1053 - 1056
  • 3Nagata K, Sone N, and Tamura T. Inhibitory Activities of Lansoprazole against Respiration in Helicobacter pylori. Antimicrobial Agents and Chemotherapy, 2001,45(5):1522-1527
  • 4Ohara T, Goshi S, Taneike I, et al. Inhibitory action of a novel proton pump inhibitor, rabeprazole, and its thioether derivative against the growth and motility of clarithromycin - resistant Helicobacter pylori. Helicobacter, 2001,6(2): 125 - 129.In- Vitro Activity of Rabeprazole (Bolite) against Helicobacter pylori.Helicobacter,2001,6(2):125-129

同被引文献36

  • 1钟英强,许哲,夏忠胜,陈其奎,曾志勇,黄志清.以加替沙星为基础的三联疗法根除幽门螺杆菌感染的疗效和费用分析[J].中国新药与临床杂志,2005,24(5):394-397. 被引量:19
  • 2王瑞彬,丁惟培.质子泵抑制剂的开发及研究现状[J].中国药物化学杂志,1995,5(1):73-78. 被引量:12
  • 3成虹,胡伏莲.北京地区幽门螺杆菌耐药情况及其变化趋势[J].中华医学杂志,2005,85(39):2754-2757. 被引量:176
  • 4钟英强,郭佳念,许哲,颜蓉,李惠君,曾志勇.以雷贝拉唑与加替沙星为基础的三联疗法作为幽门螺杆菌感染根除失败的补救方案的研究[J].中国新药杂志,2007,16(13):1046-1049. 被引量:7
  • 5Hunt RH, Megraud F, Leon - Bma R, et al. World congress of gas- troenterology(WGO - OMGE) - practice guideline: Helicobacter py- lori in developing countries[ J ]. Chinese Journal of Gastroenterology, 2007,12( 1 ) :40 -52.
  • 6Gisbert JP, Morena F. Systematic review and meta - analysis : levo- floxacin - based rescue regimens after Helicobacter pyroli treatmentfaih, re[ J]. Aliment Pharmacol Ther, 2006,23 ( 1 ) :35 -44.
  • 7Miwa H,Yamada T,Sato K,et a1.Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection:comparison of 20 and 40 mg rabeprazole with 60 mg lansoprazole.Dig Dis Sci,2000,45:77—82.
  • 8Ohara T,Goshi S,Taneike I,et a1.Inhibitory action of a novel proton pump inhibitor,rabeprazole,and its thioether derivative against the growth and motility of clarithromycin-resistant Helicobacter pylori.Helicobacter,2001,6:125-129.
  • 9Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole [J]. Aliment Pharmacol Ther, 1999,13(suppl3) :27 - 36
  • 10BOYANOVA L, MENTIS A, GUBINA M, et al. The status of antimicrobial resistance of Helicobacter pyroli in eastern Europe [ J ]. Clin Microbiol Infect, 2002,8 ( 7 ) :388 - 396.

引证文献7

二级引证文献64

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部